Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ABVC Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABVC
Nasdaq
8731
https://abvcpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ABVC Biopharma Inc
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation
- Jun 21st, 2022 12:30 pm
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
- Jun 16th, 2022 12:30 pm
ABVC BioPharma Announces Termination of Two Contracts
- Jun 10th, 2022 12:30 pm
ABVC: Enrollment in ABV-1505 Part 2 ADHD Clinical Study Continues; First Patient Begins Treatment
- Jun 7th, 2022 5:10 pm
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
- Jun 1st, 2022 12:30 pm
ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners
- May 25th, 2022 12:30 pm
Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines
- May 23rd, 2022 11:30 am
ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results
- May 16th, 2022 9:46 pm
WallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering
- May 16th, 2022 7:25 pm
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
- May 13th, 2022 12:30 pm
WallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering
- May 12th, 2022 1:00 pm
ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering
- May 12th, 2022 12:30 pm
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
- May 10th, 2022 12:30 pm
ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process
- May 5th, 2022 12:30 pm
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed
- May 3rd, 2022 12:30 pm
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
- Apr 28th, 2022 12:30 pm
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
- Apr 26th, 2022 12:30 pm
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
- Mar 31st, 2022 8:18 pm
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
- Mar 23rd, 2022 1:25 pm
ABVC: Lead Products Move Closer To Potential Approval; Important Clinical Studies Advancing
- Mar 8th, 2022 11:15 am
Scroll